Tumor Necrosis
Inhibitor class PsO treatments exhibit similar efficacy in mitigating PsA risk
Patients treated with interleukin-23i or IL-12/23i for psoriasis exhibited similar rates of risk for developing psoriatic arthritis, according to a study.
TNF-Blocking Therapies
Biologics Targeting Interleukin-17
BLOG: We don’t know what dry eye is, but we sure have a lot of ways to treat it
Ever heard of a helical collagen intercalator? How about a TRPM8 agonist? Maybe RASP as a target of treatment?
Extreme heat exposure may impair immune response, increase inflammation
Researchers in Kentucky identified mechanisms by which heat exposure caused immune response that may increase inflammation.
‘Perianal fistulas are preventable’ in pediatric Crohn’s with early anti-TNF therapy
LAS VEGAS — Early treatment with tumor necrosis antagonist was linked to 79% reduced odds of patients with pediatric Crohn’s disease developing perianal fistulizing complications, noted a presenter at the Crohn’s & Colitis Congress.
Two inflammatory markers independently predict heart disease risk
Among adults presenting with chest pain, those with CAD confirmed by angiography had significantly lower levels of the cytokines interleukin-4 and interleukin-17 compared with those without CAD, data show.
Acne improves with TNF inhibitors, but treatment may also incite condition
While tumor necrosis factor-alpha inhibitors have shown positive results in the treatment of acne, the use of these inhibitors for other conditions may incite new acne development, according to a study.
Libtayo effective in killing HCC tumors prior to resection
Neoadjuvant immunotherapy Libtayo administered before surgical resection led to tumor necrosis in about one-third of patients with hepatocellular carcinoma, according to data published in The Lancet Gastroenterology and Hepatology.